Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson VELCADE [reported separately through FY2020Q4] by Year
VELCADE (bortezomib) [reported separately through FY2020Q4] — U.S. sales ($M) ($M)
Johnson & Johnson VELCADE [reported separately through FY2020Q4]: $0M in FY2020. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
Source: Form 10-K (filed 2021-02-22) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | VELCADE (bortezomib) [reported separately through FY2020Q4] — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Jan 3, 2021 | 0 | – | Form 10-K (filed 2021-02-22) ↗ |
| FY2019 | Dec 29, 2019 | 0 | – | Form 10-K (filed 2021-02-22) ↗ |
| FY2018 | Dec 30, 2018 | 0 | – | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 0 | – | Form 10-K (filed 2019-02-20) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson VELCADE [reported separately through FY2020Q4] ($M), annual FY2016–FY2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-velcade-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.